[go: up one dir, main page]

AU6080294A - Antisense molecules directed against genes of the (raf) oncogene family - Google Patents

Antisense molecules directed against genes of the (raf) oncogene family

Info

Publication number
AU6080294A
AU6080294A AU60802/94A AU6080294A AU6080294A AU 6080294 A AU6080294 A AU 6080294A AU 60802/94 A AU60802/94 A AU 60802/94A AU 6080294 A AU6080294 A AU 6080294A AU 6080294 A AU6080294 A AU 6080294A
Authority
AU
Australia
Prior art keywords
raf
directed against
antisense molecules
oncogene family
molecules directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU60802/94A
Inventor
Larry A Denner
Richard A.F. Dixon
Ajay A Rege
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encysive Pharmaceuticals Inc
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of AU6080294A publication Critical patent/AU6080294A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU60802/94A 1992-12-31 1993-12-28 Antisense molecules directed against genes of the (raf) oncogene family Abandoned AU6080294A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99971092A 1992-12-31 1992-12-31
US999710 1992-12-31
PCT/US1993/012603 WO1994015645A1 (en) 1992-12-31 1993-12-28 Antisense molecules directed against genes of the raf oncogene family

Publications (1)

Publication Number Publication Date
AU6080294A true AU6080294A (en) 1994-08-15

Family

ID=25546620

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60802/94A Abandoned AU6080294A (en) 1992-12-31 1993-12-28 Antisense molecules directed against genes of the (raf) oncogene family

Country Status (2)

Country Link
AU (1) AU6080294A (en)
WO (1) WO1994015645A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689267B2 (en) * 1994-05-31 1998-03-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of RAF gene expression

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015646A1 (en) * 1993-01-07 1994-07-21 Thomas Jefferson University Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (en) * 1994-05-31 1999-07-15 파샬 비. 린네 Antisense Oligonucleotide Regulation of Rafgene Expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
AU2092597A (en) * 1996-03-07 1997-09-22 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6803360B1 (en) 1996-12-30 2004-10-12 Georgetown University Compositions and methods for reducing radiation and drug resistance in cells
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
AU4556800A (en) * 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
DE10020138A1 (en) * 2000-04-14 2001-10-31 Ulf R Rapp Nucleic acid coding for at least one partial sequence with a MEKK1 binding site
IL155991A0 (en) 2000-12-01 2003-12-23 Max Planck Gesellschaft Rna interference mediating small rna molecules
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
AU2003228238A1 (en) * 2002-05-20 2003-12-12 Neopharm, Inc. Method for reducing platelet count

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689267B2 (en) * 1994-05-31 1998-03-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of RAF gene expression

Also Published As

Publication number Publication date
WO1994015645A1 (en) 1994-07-21

Similar Documents

Publication Publication Date Title
AU6080294A (en) Antisense molecules directed against genes of the (raf) oncogene family
AU5616794A (en) Chemical vessel environmental chamber
PL315687A1 (en) Comparative analysis of gene transcript
HK1003588B (en) Immersion heaters
GB9210273D0 (en) Dna
AU1768192A (en) Rna delivery vector
AU8260491A (en) Dna sequencing
AU3211793A (en) Electromagnetic flowmeter
AU5568694A (en) Stable oligonucleotides
AU7404794A (en) Cardioplegia filter
EP0754187A4 (en) Growth arrest homeobox gene
AU2351492A (en) Process for the preparation of middle distillates
AU3402693A (en) Substituted phenylacetamides
AU2880392A (en) Chromatographic separation of phosphorothioate oligonucleotides
AU639339B2 (en) Improved coatings
AU3730093A (en) Methods of treating diabetes
IL107198A0 (en) Antisense oligonucleotide inhibition of the ras gene
AU3729493A (en) Cyclobutyl antisense oligonucleotides, methods of making and use thereof
AU4744893A (en) Sample core stabilization
AU3402793A (en) Imidazolyl-substituted phenylacetamides
AU3462193A (en) Polyalkylcyanoacrylate nanocapsules
AU2285592A (en) Improved coating solution
AU5371694A (en) Use of the tarchonanthus camphoratus
AU3292393A (en) Treating liquids
AU1893192A (en) Dna silver staining